Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy

NCT05250856 is registered in ClinicalTrials.gov with COUR Pharmaceutical Development Company, Inc. as lead sponsor.

NCT NCT05250856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05250856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 14, 2022
Completion date
December 12, 2023
Enrollment
15 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy